论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yang L, He W, Xie Q, Liu S, Kong P, Jiang C, Zhang B, Xia L
Received 13 July 2018
Accepted for publication 31 August 2018
Published 15 November 2018 Volume 2018:10 Pages 5649—5658
DOI https://doi.org/10.2147/CMAR.S180173
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
Background: Population-based
incidence evaluations and prognosis assessments of brain metastasis (BM) at
diagnosis of colorectal cancer (CRC) are lacking. Our study sought to determine
the incidence of BM in CRC patients, median survival of patients with BM, and
the risk factors of BM in CRC.
Patients and methods: Patients
diagnosed with CRC were identified using the Surveillance, Epidemiology, and
End Results database. Multivariable logistic and Cox regression analyses were
performed to identify predictors of the presence of BM at CRC diagnosis and the
factors associated with poor survival. Kaplan–Meier analysis was used to
estimate the survival difference between subgroups.
Results: We identified
170,793 adult patients diagnosed with CRC between 2010 and 2013. From these
patients, we identified 401 patients with BM at the time of CRC diagnosis,
which represents 0.23% of the entire patient CRC cohort and 1.3% of the
patients with metastatic disease to any site. Median survival of patients with
BM was 7.0 months, and the survival could increase to 15.59 months if there was
no metastasis to other organs. We found that extracranial metastases number,
tumor site, and pathology type were associated with BM at CRC diagnosis.
Conclusion: The findings of
this study indicate the incidence and prognosis for patients with BM at the
time of CRC diagnosis. Our findings lend support for positive treatment for BM
without metastasis to other organs.
Keywords: colorectal
cancer, brain metastasis, tumor site, prognosis
